Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a string of investigational meds missing the mark in the indication. | Alector’s Abbvie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study,

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its remaining pipeline. Learn more on ALEC stock here.

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech expects its current cash position to last it through 2026.